Bevacizumab plus Capecitabine versus Capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
| dc.contributor.author | Cunningham, D | |
| dc.contributor.author | Lang, I | |
| dc.contributor.author | Marcuello, E | |
| dc.contributor.author | Lorusso, V | |
| dc.contributor.author | Ocvirk, J | |
| dc.contributor.author | Shin, D | |
| dc.contributor.author | Jonker, D | |
| dc.contributor.author | Osborne, S | |
| dc.contributor.author | Andre, N | |
| dc.contributor.author | Waterkamp, D | |
| dc.contributor.author | Saunders, Mark P | |
| dc.date.accessioned | 2013-12-20T10:42:16Z | |
| dc.date.available | 2013-12-20T10:42:16Z | |
| dc.date.issued | 2013-10 | |
| dc.identifier.citation | Bevacizumab plus Capecitabine versus Capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. 2013, 14 (11):1077-85 Lancet Oncol | en |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 24028813 | |
| dc.identifier.doi | 10.1016/S1470-2045(13)70154-2 | |
| dc.identifier.uri | http://hdl.handle.net/10541/308832 | |
| dc.description.abstract | Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorectal cancer. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The lancet oncology | en |
| dc.title | Bevacizumab plus Capecitabine versus Capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. | en |
| dc.type | Article | en |
| dc.contributor.department | Royal Marsden Hospital, London, UK. | en |
| dc.identifier.journal | The Lancet Oncology | en |
| html.description.abstract | Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorectal cancer. |